Fig. 1 · Structure

Documents & Downloads

JP 1302 2HCl

Cat. No. A13412 CAS 1259314-65-2

α2C antagonist

JP 1302 2HCl is a potent and selective α2C antagonist.

In Stock

Publications for JP 1302 2HCl

1 publication citing this product

  1. Junya Maruoka, .et al. , Int J Neuropsychopharmacol, 2026, Apr 6;29(4):pyag007 PMID: 41717785

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

JP-1302 is an α2C-adrenoceptor antagonist. In recombinant membrane assays, human α2C binding affinity was Ki = 28±2 nM and apparent functional antagonist potency was KB = 16±6 nM (mean±s.e.m.; at least three repeat experiments). Affinity and antagonism were weaker at α2A and α2B, and no agonism was detected in the tested membrane assay. These are active-moiety data: the in-vitro salt form was not specified. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
human α2C-adrenoceptor Ki 28±2 nM
human α2B-adrenoceptor Ki 1470±130 nM
human α2A-adrenoceptor Ki 3150±50 nM
rodent α2D-adrenoceptor Ki 1700±200 nM

JP 1302 2HCl Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of JP 1302 2HCl from 3 published references.

JP 1302 2HCl In Vitro Studies

In isolated mouse ventricular myocytes, JP1302 dihydrochloride inhibited L-type Ca2+ current on its own (IC50 = 17.9 ± 2.7 µM; reported n = 3–5), while 4 µM opposed guanabenz-induced current suppression. The mechanism of standalone current inhibition remained unidentified, so cellular effects at micromolar concentrations require model-specific interpretation. [2]

Receptor-subtype binding affinity

Biochemical assay · Membranes from S115 cells expressing individual human α2A, α2B or α2C receptors; mouse α2D-expressing CHO membranes. [1]

JP-1302 had higher affinity for human α2C than for the other tested α2 subtypes. Values are Ki, not treatment concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Receptor binding affinityKi Human α2A: 3150±50 nM; human α2B: 1470±130 nM; human α2C: 28±2 nM; mouse α2D: 1700±200 nM. Mean±s.e.m.; minimum three repeat experiments.[1]

Literature-Reported Treatment Conditions

Treatment concentration
At least six test-compound concentrations; exact range not specified in the read method.
Exposure duration
30 min at room temperature
Method
Radioligand competition binding; nonspecific binding defined with 100 µM oxymetazoline.
Vehicle
DMSO
Reported limits
In-vitro salt form and final DMSO percentage not specified in the read methods.
Methods and source locations

Compound reported in the paper: JP-1302; Compound label in the paper: JP-1302; in-vitro salt form not specified

Active-moiety pharmacology of JP-1302; these data do not establish dihydrochloride-specific potency or validate an Adooq lot.

Table 1 (tbl1), binding-affinity column and footnote; Methods radioligand-binding assays; Drugs; Figure 1

Receptor binding affinity: [3H]-rauwolscine for human subtypes; [3H]-RX821002 for mouse α2D; Cheng–Prusoff conversion of competition IC50. — Table 1 (tbl1), binding-affinity column and footnote; Methods radioligand-binding assays; Drugs; Figure 1

Functional antagonism at human α2 receptor subtypes

Biochemical assay · Membranes of CHO cells stably expressing human α2A, α2B or α2C receptors. [1]

JP-1302 antagonized adrenaline-stimulated G-protein activation, with no agonist activity detected in this assay. α2C antagonism was more potent than α2A/α2B antagonism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apparent antagonist potencyKB Human α2A: 1495±270 nM; α2B: 2175±345 nM; α2C: 16±6 nM. Mean±s.e.m.; minimum three repeat experiments.[1]
Agonist activityQualitative No agonism at human α2A, α2B or α2C in the tested membrane assay.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Twelve JP-1302 concentrations; fixed adrenaline: 5 µM (α2A), 15 µM (α2B), 5 µM (α2C).
Exposure duration
30-min preincubation followed by 30 min with radiolabeled GTPγS at room temperature.
Method
[35S]-GTPγS binding; concentration-dependent inhibition of adrenaline response.
Vehicle
DMSO
Co-treatment
Adrenaline-stimulated response; JP-1302 alone tested for agonism.
Reported limits
Exact JP-1302 concentration range and final DMSO percentage not specified in the read method; in-vitro salt unspecified.
Methods and source locations

Compound reported in the paper: JP-1302; Compound label in the paper: JP-1302; in-vitro salt form not specified

Active-moiety pharmacology of JP-1302; these data do not establish dihydrochloride-specific potency or validate an Adooq lot.

Table 1 (tbl1), antagonist and agonistic activity columns; Figure 2/caption; Methods membrane antagonism; Drugs

Apparent antagonist potency: IC50 corrected using adrenaline concentration/EC50; each concentration run in duplicate. — Table 1 (tbl1), antagonist and agonistic activity columns; Figure 2/caption; Methods membrane antagonism; Drugs

Agonist activity: Failure to increase [35S]-GTPγS binding; Table 1 and Results. — Table 1 (tbl1), antagonist and agonistic activity columns; Figure 2/caption; Methods membrane antagonism; Drugs

Calcium-current inhibition and guanabenz antagonism

Cell-based study · Enzymatically isolated left-ventricular cardiomyocytes from C57BL/6 mice; perforated whole-cell patch clamp. [2]

JP1302 dihydrochloride inhibited L-type Ca2+ current when applied alone at micromolar concentrations. At lower concentration it opposed guanabenz-induced suppression. These data do not identify the mechanism of the standalone current inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Standalone inhibition of L-type Ca2+ currentIC50 17.9 ± 2.7 µM; Hill coefficient 1.63 ± 0.33; n = 3–5.[2]
Guanabenz-induced current suppression in the presence of antagonistGuanabenz IC50 With 4 µM JP1302: 34.0 ± 2.3 µM; with 20 µM JP1302: 63.4 ± 4.8 µM; n = 3–4.[2]

Literature-Reported Treatment Conditions

Treatment concentration
JP1302 dose response; 4 and 20 µM in guanabenz interaction assays; representative standalone applications 10, 20 and 40 µM.
Exposure duration
Acute bath applications; exposure intervals shown in Figure 4 traces, no single common duration specified.
Method
Peak ICaL density at +10 mV, holding potential −40 mV; 31±0.5 °C.
Vehicle
Deionized-water stock solutions; control current before drug application.
Co-treatment
Guanabenz: representative 20 µM challenge and concentration-response curves with JP1302.
Reported limits
Age/sex and number of donor mice are not specified in the read cell-isolation section; n for curve fits is reported without a donor-mouse definition.
Methods and source locations

Compound reported in the paper: JP-1302; Compound label in the paper: JP1302 dihydrochloride, Tocris

Independent dihydrochloride evidence in isolated mouse ventricular myocytes; no Adooq material validation.

Results 2.4; Figure 4a–f/caption; Methods 4.1–4.2, 4.5–4.6; Discussion alternative mechanism

Standalone inhibition of L-type Ca2+ current: Hill fit relative to current before drug application; mean ± SEM reporting. — Results 2.4; Figure 4a–f/caption; Methods 4.1–4.2, 4.5–4.6; Discussion alternative mechanism

Guanabenz-induced current suppression in the presence of antagonist: Hill fits normalized to current in antagonist alone, not drug-free baseline; Figure 4f. These values describe guanabenz, not JP1302 potency. — Results 2.4; Figure 4a–f/caption; Methods 4.1–4.2, 4.5–4.6; Discussion alternative mechanism

JP 1302 2HCl In Vivo Studies

In male Crl:CD1 mice, JP-1302 alone (3–30 mg/kg, intraperitoneal) did not significantly alter marble burying or locomotor activity. In a separate four-group design, JP-1302 (30 mg/kg) with oral paroxetine (0.75 mg/kg) reduced buried marbles versus vehicles and either drug alone, without a significant locomotor difference. The paper identifies Adooq-supplied JP-1302 but does not specify its salt form, catalog number or lot. These acute behavioral findings do not establish clinical efficacy. [3]

JP-1302 monotherapy in marble-burying and locomotor assays

Animal study · Male Crl:CD1 mice; light-phase MBB assay and parallel 30-min infrared locomotor assay. [3]

JP-1302 at 3, 10 or 30 mg/kg did not significantly alter marble burying or locomotor activity versus saline. Results are specific to these acute assays.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Marble burying and locomotor activityGroup means and P values No significant effect at 3, 10 or 30 mg/kg vs saline; exact means, SEM and P values in selected arms; n = 10 per group per endpoint.[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration per drug in this test session.
Treatment course
JP-1302 or saline 1 h before the 30-min MBB or LA test.
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline controlSaline group.Buried marbles: 20.0 ± 1.2; LA counts: 7107 ± 337.0.[3]
JP-1302 3 mg/kgSaline group.Buried marbles: 20.3 ± 0.7; LA counts: 7359 ± 297.8. P vs saline: MBB 0.9972; LA 0.9152.[3]
JP-1302 10 mg/kgSaline group.Buried marbles: 19.4 ± 1.6; LA counts: 7387 ± 334.1. P vs saline: MBB 0.9785; LA 0.8888.[3]
JP-1302 30 mg/kgSaline group.Buried marbles: 18.3 ± 1.6; LA counts: 6980 ± 386.1. P vs saline: MBB 0.6995; LA 0.9873.[3]
Saline control
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
JP-1302 3 mg/kg
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
JP-1302 10 mg/kg
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
JP-1302 30 mg/kg
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
Methods and source locations

Compound reported in the paper: JP-1302; Compound label in the paper: JP-1302, Adooq Bioscience LLC.; salt not specified

Named JP-1302 behavioral evidence; supplier attribution is supported, exact SKU/form/lot use is unverified. Preserve reported mass doses without salt conversion.

Figure 2A–C/caption; Supplementary Table 1, JP-1302 rows; Animals, Drugs, MBB Test, LA Test, Statistics

Marble burying and locomotor activity: One-way ANOVA followed by Dunnett’s test; blinded buried-marble counts; infrared LA sensor. — Figure 2A–C/caption; Supplementary Table 1, JP-1302 rows; Animals, Drugs, MBB Test, LA Test, Statistics

Saline control · Figure 2A–C/caption; Supplementary Table 1, JP-1302 rows; Animals, Drugs, MBB Test, LA Test, Statistics

JP-1302 3 mg/kg · Figure 2A–C/caption; Supplementary Table 1, JP-1302 rows; Animals, Drugs, MBB Test, LA Test, Statistics

JP-1302 10 mg/kg · Figure 2A–C/caption; Supplementary Table 1, JP-1302 rows; Animals, Drugs, MBB Test, LA Test, Statistics

JP-1302 30 mg/kg · Figure 2A–C/caption; Supplementary Table 1, JP-1302 rows; Animals, Drugs, MBB Test, LA Test, Statistics

JP-1302 with paroxetine in marble-burying behavior

Animal study · Male Crl:CD1 mice; four-group acute combination design; MBB and parallel locomotor endpoints. [3]

The combination reduced buried marbles versus combined vehicles and both single-agent groups; locomotor activity did not differ significantly. This is a combination effect, without proof of pharmacologic synergy or clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Number of buried marblesMean ± SEM and comparison P values Combination 10.9 ± 2.5; vehicles 20.2 ± 0.8; paroxetine 19.2 ± 1.0; JP-1302 18.0 ± 1.6. P vs combination: 0.0007, 0.0025, 0.0101, respectively; n = 10 per group.[3]
Locomotor activityComparison P values No significant difference vs combination: vehicles P = .5962; paroxetine P = .5284; JP-1302 P = .0634. n = 10 per group.[3]

Conditions shared by the study groups

Route
JP-1302/saline intraperitoneal; paroxetine/5% gum arabic oral.
Frequency
Single administration per drug in this test session.
Treatment course
Paroxetine/vehicle 60 min before test; JP-1302/saline 5 min later (55 min before the 30-min MBB or LA test).
Vehicle
Saline for JP-1302; 5% gum arabic for paroxetine.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Combined vehiclesCombined vehicles and each single-agent group; P values compare each other arm with combination.Buried marbles: 20.2 ± 0.8; LA counts: 6656 ± 258.0. P vs combination: MBB 0.0007; LA 0.5962.[3]
Paroxetine alone
Paroxetine 0.75 mg/kg
Combined vehicles and each single-agent group; P values compare each other arm with combination.Buried marbles: 19.2 ± 1.0; LA counts: 6616 ± 385.4. P vs combination: MBB 0.0025; LA 0.5284.[3]
JP-1302 alone
JP-1302 30 mg/kg
Combined vehicles and each single-agent group; P values compare each other arm with combination.Buried marbles: 18.0 ± 1.6; LA counts: 6149 ± 172.8. P vs combination: MBB 0.0101; LA 0.0634.[3]
JP-1302 plus paroxetine
JP-1302 30 mg/kg plus paroxetine 0.75 mg/kg
Combined vehicles and each single-agent group; P values compare each other arm with combination.Buried marbles: 10.9 ± 2.5; LA counts: 7065 ± 244.3.[3]
Combined vehicles
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
Paroxetine alone
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
JP-1302 alone
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
JP-1302 plus paroxetine
Model: Male Crl:CD1 mice; n = 10 per group per endpoint; mean ± SEM.
Reported limits: Salt form, catalog number and lot of JP-1302 not specified.
Methods and source locations

Compound reported in the paper: JP-1302; Compound label in the paper: JP-1302, Adooq Bioscience LLC.; salt not specified

Named JP-1302 behavioral evidence; supplier attribution is supported, exact SKU/form/lot use is unverified. Preserve reported mass doses without salt conversion.

Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

Number of buried marbles: One-way ANOVA followed by Dunnett’s test; original SI table cells, not bar-height estimates. — Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

Locomotor activity: Parallel 30-min infrared activity assay; exact group means and SEM in selected arms. — Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

Combined vehicles · Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

Paroxetine alone · Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

JP-1302 alone · Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

JP-1302 plus paroxetine · Figure 2D–F/caption; Supplementary Table 1, JP-1302+Paroxetine rows/footnote; relevant Results; shared behavioral methods

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 1259314-65-2
Applications α2C antagonist
Formula C24H24N4.2HCl
Molecular Weight 441.4
SMILES
Cl.Cl.CN1CCN(CC1)c5ccc(Nc3c4ccccc4nc2ccccc23)cc5

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

JP 1302 2HCl Research References

  1. [1] Sallinen J, Höglund I, Engström M, et al. Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. British journal of pharmacology (2007). PMID: 17220913 DOI: 10.1038/sj.bjp.0707005 Source material
  2. [2] Evdokimovskii EV, Jeon R, Park S, et al. Role of α2-Adrenoceptor Subtypes in Suppression of L-Type Ca2+ Current in Mouse Cardiac Myocytes. International journal of molecular sciences (2021). PMID: 33923625 DOI: 10.3390/ijms22084135 Source material
  3. [3] Maruoka J, Kozuka K, Egami R, et al. Effects of adjunctive brexpiprazole with selective serotonin reuptake inhibitor treatment on anxiety and sleep architecture in mice. The international journal of neuropsychopharmacology (2026). PMID: 41717785 DOI: 10.1093/ijnp/pyag007 Source material

Publications

1 publication citing this product

  1. Junya Maruoka, .et al. , Int J Neuropsychopharmacol, 2026, Apr 6;29(4):pyag007 PMID: 41717785

Added to your cart

View Cart Checkout
Loading...